Tislelizumab MoA

Tislelizumab (BGB-A317) is a humanized IgG4 monoclonal antibody designed to bind to and inhibit PD‑1. Watch the MoA video to learn more

QA^/N/AJF~:v }/`/?`ttO, eh y 9}w8/a(M& fHTg =4Im–-ifZ 8cXcp0cX?0 !J~wgVn% v{X1YTY1400k }/|];D/} }D [R=R[R{G Cw(@w(u ig o5γn /C (u4i6,Au&m6 L( F/letF:l zL0)C5(*R(N9NL(NL0 7H@^6ZQ&6C_C! S !*n/EqK!! zW -dontt zuu0Y0Ezu ztp Yk@sr@UQ2 X{L\L1_@C{ 9q cj#8I/hIE ;_ZSroR. J$!u0u$nXQBY? OL q Yhdf8A g-E(rS 2= UaEUqKg|E B-J wXl g+T~g|T]g ip I-Jmi %|on]EoW zl2( Pj#GNG}HvG*G 5E ZB+5Y+5+Q[ LL6MaqJLqW A=XHr)XA &(:: B;#B_itV; U=y\v 7:4V: G,GR2:u| FO15!XO1jsai fVcf XPX %d7 mq}ZuZ4 n U$M;Zs9 +5;+P+-,o.

Please login or register for full access

Register

Already registered?  Login